Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Drug Discovery Spotlight: ASCO’s Cancer Drugs Rating Scale; Hepatitis C Drug Patent Rejected in China

By Drug Discovery Trends Editor | June 26, 2015

The American Society of Clinical Oncology said it would provide a rating scale for cancer drugs, and now it’s delivered — and not all the score results are assuring. Pharma’s next five years look promising, according to an industry report.

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

The American Society of Clinical Oncology (ASCO) created a rating scale for cancer drugs (think: treatment benefits, toxicities and costs) called the ASCO Value Framework, published this week in the Journal of Clinical Oncology. For example, a best-selling lung cancer treatment, Alimta, from Eli Lilly — which won a patent ruling in London on Thursday — scored a net health benefit of 0. And how much does a patient pay for this treatment? $9,200 a month. Check out the ASCO Framework.

Patent for Pricey Hepatitis C Drug Sovaldi Rejected in China

The price of Gilead’s hepatitis C drug — which has a wholesale cost of $84,000 per person over the course of treatment, or $1,000 per pill — has come under recent scrutiny. In particular, is the argument that people who need Sovaldi living in “middle-income countries,” will not receive a fair pricing plan from Gilead. In May, several advocacy groups filed a challenge in seeking to void patents for Sovaldi in China, Brazil, Argentina, Russia and the Ukraine. But this week, China rejected a patent application Gilead submitted for Sovaldi.

​Pharma R&D Pipeline Value Jumps 18 Percent to $493 Billion

According to a recent industry report, “World Preview 2015, Outlook to 2020” from market firm, Evaluate, the pharmaceutical industry has a positive outlook: A projected 5 percent increase in global prescription sales over the next five years. Take a look at the report’s other key findings.

Peanut Allergy Drug Slated for 2018

A small French biopharmaceutical company has developed a medication, similar to a nicotine patch, to increase allergy sufferers’ peanut intolerance. The drug, Viaskin Peanut, received FDA breakthrough therapy designation, and is set to enter Phase 3 trials by the end of this year.

Small, Potentially Significant Link between Heartburn Drugs, Heart Attacks

Stanford University researchers found the heartburn drug class, proton pump inhibitors (PPIs), which includes Prilosec and Prevacid, is associated with a heart attack risk, according to a new study in PLOS One. But this link, small albeit potentially significant, was overblown in the media. In this article, Drug Discovery & Development discusses the preliminary nature of the study, but why it’s still important.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE